Trials / Completed
CompletedNCT05852769
A Study to Evaluate the Drug-drug Interaction Potential of BMS-986196 in Healthy Participants
A Phase 1, Single-center, Open-label, Sequential Study to Evaluate the Drug-drug Interaction Potential of BMS-986196 in Healthy Participants
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 18 (actual)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
This study is designed to assess the effect of BMS-986196 on the drug levels of caffeine, montelukast, flurbiprofen, omeprazole, midazolam, digoxin, and pravastatin in healthy participants.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BMS-986196 | Specified dose on specified days |
| DRUG | Caffeine | Specified dose on specified days |
| DRUG | Montelukast | Specified dose on specified days |
| DRUG | Flurbiprofen | Specified dose on specified days |
| DRUG | Omeprazole | Specified dose on specified days |
| DRUG | Midazolam | Specified dose on specified days |
| DRUG | Digoxin | Specified dose on specified days |
| DRUG | Pravastatin | Specified dose on specified days |
Timeline
- Start date
- 2023-05-31
- Primary completion
- 2023-08-24
- Completion
- 2023-08-24
- First posted
- 2023-05-10
- Last updated
- 2023-09-26
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05852769. Inclusion in this directory is not an endorsement.